Pfizer is still the only big pharma to have followed Bristol's lead in going all-in on the mechanism.
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
The company’s massive clinical programme with BMS-986165 is set to deliver its first pivotal data later this year.